Placeholder Banner

New Executive Order Critical to Protecting Patients and Public Health

September 20, 2019
Media Contact

Washington, D.C. (September 20, 2019) – President Trump has signed an executive order focused on spurring the development of new vaccine technologies, prioritizing the production of influenza vaccines and identifying strategies for communicating the importance of influenza vaccination. Ahead of what is expected to be a severe flu season, the Administration has made clear that ensuring patients have access to safe and effective treatments is of great importance.

“There are few national priorities more important than protecting the American people from the next possible pandemic outbreak. The president’s own economic advisers have warned that such an event could cost up to $4 trillion and result in the loss of hundreds of thousands of lives. And as many Americans experience each year, seasonal influenza poses as a serious and even deadly threat,” said BIO’s President and CEO, Jim Greenwood. 

“I am pleased to see the Administration take action on this vitally important issue. BIO shares the Administration’s strong commitment to investing in and promoting novel technologies that will help address these challenges in way that protects both the public’s health and our nation’s security.”

Read the full executive order here.

Read the Council of Economic Advisers report here.

Discover More
Event Highlighted Leadership in Vaccine Development and Regional Growth in Biotechnology Innovation Gaithersburg, MD (September 24, 2020) – Today, Maryland Governor Larry Hogan and Dr. Michelle McMurry-Heath, President & CEO of Biotechnology…
The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee members for the 2020-2021 term. Additionally, eight new board directors and four new section governing board chairs and vice chairs…
Following the announcement that Dr. Moncef Slaoui will lead the Trump Administration's "Operation Warp Speed" initiative, BIO’s President and CEO, Jim Greenwood, issued the following statement:  “Dr. Moncef Slaoui is an excellent choice…